Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma

Recruiting

Phase 2

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05907759

Conditions

Lymphoma, Primary Effusion

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Daratumumab SC

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-02. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-03-11.